Entremed (ENMD)

[tborges]

Sort of... Enmd was issued a patent for methods of treatment and formulations, but the licensing of 2-methoxy estradiol is still controlled by CHB:

"...EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced the issuance of a U.S. patent covering methods of treatment and formulations for its lead clinical-stage compound, 2-methoxyestradiol (2ME2). Panzem® NCD, an oral formulation of 2ME2, is currently in Phase 2 clinical trials for cancer. Panzem® is also in preclinical development for rheumatoid arthritis.

Patent No. 7,081,477, entitled "Estrogenic Compounds as Anti-Mitotic Agents," contains claims granted by the U.S. Patent Office covering methods of using 2ME2 to treat diseases that are characterized by abnormal cell division (mitosis), including cancer and non-oncology diseases. The claims are independent of mechanism and cover various cancers, tumor metastases, vascular abnormalities, inflammatory and immune disorders, and abnormal angiogenesis that accompanies diseases such as rheumatoid arthritis. The patent also covers multiple formulations for 2ME2. The inventors are Drs. Robert D'Amato and Judah Folkman from Children's Hospital Boston. Children's Hospital has licensed 2ME2 exclusively to EntreMed..."